https://www.pharmaradar360.com/article/fda-advisory-panel-to-assess-peptide-bulk-drug-substances-from-obesity-to-opioid-5c21d5c320866f96Pharma Surgeen2026-07-07T16:08:22.000ZFDA Advisory Panel to Assess Peptide Bulk Drug Substances from Obesity to Opioidhttps://www.pharmaradar360.com/article/this-small-cap-biotech-is-turning-heads-on-wall-street-4be630ea30a43fa4Pharma Surgeen2026-07-07T16:05:00.000ZThis Small-Cap Biotech Is Turning Heads on Wall Streethttps://www.pharmaradar360.com/article/fda-s-regulatory-outlook-897a255287271b38Pharma Surgeen2026-07-07T16:00:00.000ZFDA’s regulatory outlookhttps://www.pharmaradar360.com/article/biotech-supply-chain-market-size-share-growth-report-2034-0bf1acaaa5e8abc0Pharma Surgeen2026-07-07T15:41:40.000ZBiotech Supply Chain Market Size, Share | Growth Report [2034]https://www.pharmaradar360.com/article/novartis-to-acquire-adc-biotech-myricx-bio-for-1-5bn-56b40655fcd95954Pharma Surgeen2026-07-07T15:41:30.000ZNovartis to acquire ADC biotech Myricx Bio for $1.5bnhttps://www.pharmaradar360.com/article/veraxa-biotech-nasdaq-vrxa-shareholders-should-watch-novartis-latest-1-5b-adc-ac-7536759cd5510347Pharma Surgeen2026-07-07T15:35:31.000ZVERAXA Biotech (NASDAQ: VRXA) Shareholders Should Watch Novartis Latest $1.5B ADC Acquisitionhttps://www.pharmaradar360.com/article/astrazeneca-developing-pp-blister-packaging-for-future-drugs-d700989ebf81edf4Pharma Surgeen2026-07-07T15:26:00.000ZAstraZeneca developing PP blister packaging for future drugshttps://www.pharmaradar360.com/article/compass-says-depression-drug-has-long-lasting-benefits-2047ae6c03ce0bccPharma Surgeen2026-07-07T15:06:16.000ZCompass says depression drug has long-lasting benefitshttps://www.pharmaradar360.com/article/boehringer-bags-pvt-s-viral-vector-platform-for-cancer-vaccine-r-d-ad7dd9fe82d08aadPharma Surgeen2026-07-07T14:35:39.000ZBoehringer bags PVT’s viral vector platform for cancer vaccine R&Dhttps://www.pharmaradar360.com/article/update-class-4-medicines-defect-notification-relonchem-limited-gabapentin-relonc-c6f77c17ff41d38ePharma Surgeen2026-07-07T14:34:28.000ZUPDATE: Class 4 Medicines Defect Notification: Relonchem Limited, Gabapentin Relonchem 50mg/ml Oral Solution, EL(26)A/31https://www.pharmaradar360.com/article/package-deals-in-the-pharmaceutical-industry-and-disclosure-uk-data-a5353555b90b69abPharma Surgeen2026-07-07T14:28:38.000ZPackage deals in the pharmaceutical industry and Disclosure UK datahttps://www.pharmaradar360.com/article/disclosure-uk-2025-the-11th-year-of-disclosure-uk-data-with-industry-transparenc-0963ee0ff7faa284Pharma Surgeen2026-07-07T14:28:38.000ZDisclosure UK 2025: the 11th year of Disclosure UK data, with industry transparency continuing to growhttps://www.pharmaradar360.com/article/updates-to-the-nhs-commercial-framework-must-deliver-more-flexibility-to-support-b8379101aa8a50adPharma Surgeen2026-07-07T14:28:38.000ZUpdates to the NHS Commercial Framework must deliver more flexibility to support timely access to medicineshttps://www.pharmaradar360.com/article/greater-ambition-is-needed-to-improve-patient-access-to-innovative-medicines-48edf83374fee6f2Pharma Surgeen2026-07-07T14:28:37.000ZGreater ambition is needed to improve patient access to innovative medicineshttps://www.pharmaradar360.com/article/sbio-biotech-breakthrough-opportunities-screened-for-cash-burn-nysearca-sbio-173668196e352df4Pharma Surgeen2026-07-07T14:28:30.000ZSBIO: Biotech Breakthrough Opportunities Screened For Cash Burn (NYSEARCA:SBIO)https://www.pharmaradar360.com/article/endevica-spinout-kalohexis-submits-confidential-ipo-filing-to-develop-obesity-ch-03945869493ac098Pharma Surgeen2026-07-07T14:21:06.000ZEndevica spinout Kalohexis submits confidential IPO filing to develop obesity challenger to GLP-1shttps://www.pharmaradar360.com/article/new-heart-disease-and-strokes-plan-to-saves-thousands-of-lives-c27dc18b349b6a5aPharma Surgeen2026-07-07T14:08:23.000ZNew heart disease and strokes plan to saves thousands of liveshttps://www.pharmaradar360.com/article/sls-stock-sellas-investors-look-for-more-after-542-surge-2191fe70ced66c70Pharma Surgeen2026-07-07T14:06:10.000ZSLS Stock: SELLAS Investors Look For More After 542% Surgehttps://www.pharmaradar360.com/article/sen-rick-scott-wants-pharmaceutical-tariff-carve-out-reversed-over-china-s-force-961f5d031ac8c9f0Pharma Surgeen2026-07-07T14:03:19.000ZSen. Rick Scott wants pharmaceutical tariff carve-out reversed over China’s forced laborhttps://www.pharmaradar360.com/article/press-release-biocartis-nv-biocartis-and-discovery-life-sciences-announce-strate-8e639da711c6b5a3Pharma Surgeen2026-07-07T14:00:13.000ZPress Release Biocartis NV: Biocartis and Discovery Life Sciences Announce Strategic Collaboration to Advance Precision Oncology Diagnosticshttps://www.pharmaradar360.com/article/obesity-biotech-kalohexis-files-confidential-ipo-c8afc87a0fc6946fPharma Surgeen2026-07-07T13:49:32.000ZObesity biotech Kalohexis files confidential IPOhttps://www.pharmaradar360.com/article/saol-therapeutics-resubmits-the-new-drug-application-for-sl1009-dca-for-the-trea-6588f1bb9498345cPharma Surgeen2026-07-07T13:40:26.000ZSaol Therapeutics Resubmits the New Drug Application for SL1009 (DCA) for the Treatment of Pyruvate Dehydrogenase Complex Deficiency (PDCD), an Ultra-Rare Diseasehttps://www.pharmaradar360.com/article/world-retinoic-acid-market-analysis-forecast-size-trends-and-insights-8fb7ea9a9fe3288bPharma Surgeen2026-07-07T13:31:09.000ZWorld Retinoic Acid - Market Analysis, Forecast, Size, Trends and Insightshttps://www.pharmaradar360.com/article/cardiovascular-disease-modern-service-framework-691b4f1d262fd8caPharma Surgeen2026-07-07T13:28:10.000ZCardiovascular disease modern service frameworkhttps://www.pharmaradar360.com/article/technical-annex-cardiovascular-disease-modern-service-framework-1df86f822117b46aPharma Surgeen2026-07-07T13:28:06.000ZTechnical annex: cardiovascular disease modern service frameworkhttps://www.pharmaradar360.com/article/cardiovascular-disease-modern-service-framework-30f876a4a0b105a9Pharma Surgeen2026-07-07T13:28:00.000ZCardiovascular disease modern service frameworkhttps://www.pharmaradar360.com/article/crinetics-pharmaceuticals-acquired-by-fortress-biotech-for-10-b-bce72cb70d9e8564Pharma Surgeen2026-07-07T13:24:16.000ZCrinetics Pharmaceuticals Acquired by Fortress Biotech for $10 Bhttps://www.pharmaradar360.com/article/em-nota-entidades-do-setor-farmaceutico-alertam-para-riscos-de-produtos-sem-regi-2404c45feca06133Pharma Surgeen2026-07-07T13:16:52.000ZEm nota, entidades do setor farmacêutico alertam para riscos de produtos sem registro no Brasilhttps://www.pharmaradar360.com/article/novo-nordisk-signs-agreement-with-biotech-company-to-evaluate-semaglutide-implan-43badcf6c13842b8Pharma Surgeen2026-07-07T13:15:00.000ZNovo Nordisk signs agreement with biotech company to evaluate semaglutide implanthttps://www.pharmaradar360.com/article/purely-golden-foods-brings-biopharma-rigor-to-pet-nutrition-bizwomen-b2fbda198664da52Pharma Surgeen2026-07-07T12:58:00.000ZPurely Golden Foods brings biopharma rigor to pet nutrition - Bizwomenhttps://www.pharmaradar360.com/article/former-vertex-gsk-exec-launches-science-first-pet-nutrition-company-2059dd18016c2f89Pharma Surgeen2026-07-07T12:58:00.000ZFormer Vertex, GSK exec launches science-first pet nutrition companyhttps://www.pharmaradar360.com/article/obesity-biotech-kalohexis-confidentially-files-to-go-public-in-us-e8716115709af6bdPharma Surgeen2026-07-07T12:47:49.000ZObesity biotech Kalohexis confidentially files to go public in UShttps://www.pharmaradar360.com/article/nice-recommends-endosure-and-endotest-diagnostics-for-endometriosis-e31e9006a8a86152Pharma Surgeen2026-07-07T12:35:00.000ZNICE recommends Endosure and Endotest diagnostics for endometriosishttps://www.pharmaradar360.com/article/enterprise-value-to-ebitda-forward-of-bioray-biotech-co-ltd-tpex-7561-b336d708c238a025Pharma Surgeen2026-07-07T12:32:00.000ZEnterprise value to EBITDA forward of Bioray Biotech Co., Ltd – TPEX:7561https://www.pharmaradar360.com/article/de-risking-drug-formulation-with-ai-predictive-modelling-025dba969a2c8323Pharma Surgeen2026-07-07T12:26:34.000ZDe-risking drug formulation with AI predictive modellinghttps://www.pharmaradar360.com/article/toekomstige-europese-wetgevingen-stand-van-zaken-ff29693ca5d85483Pharma Surgeen2026-07-07T12:14:28.000ZToekomstige Europese wetgevingen: stand van zakenhttps://www.pharmaradar360.com/article/the-role-of-standards-in-the-drug-supply-chain-cd8789cc8512c491Pharma Surgeen2026-07-07T12:08:16.000ZThe Role of Standards in the Drug Supply Chainhttps://www.pharmaradar360.com/article/absentia-labs-digital-liver-model-becomes-first-ai-drug-development-tool-accepte-091754fac1473261Pharma Surgeen2026-07-07T12:06:00.000ZAbsentia Labs' Digital Liver Model Becomes First AI Drug Development Tool Accepted Into FDA Qualification Programhttps://www.pharmaradar360.com/article/therivatm-biologics-announces-regulatory-authorization-to-proceed-with-a-virage2-f63e4edb44ad899cPharma Surgeen2026-07-07T12:04:54.000ZTheriva™ Biologics Announces Regulatory Authorization to Proceed with a VIRAGE2 Phase 2a Clinical Trial to Evaluate More Frequent Dosing of VCN-01 (zabilugene almadenorepvec) in First-Line Patients with Metastatic Pancreatic Ductal Adenocarcinomahttps://www.pharmaradar360.com/article/spur-therapeutics-announces-first-patient-dosed-in-galileo-3-pivotal-clinical-tr-6af8b55a83feb474Pharma Surgeen2026-07-07T12:04:17.000ZSpur Therapeutics Announces First Patient Dosed in GALILEO-3 Pivotal Clinical Trial of FLT201 for the Treatment of Gaucher Disease Type 1https://www.pharmaradar360.com/article/enterprise-value-to-revenue-forward-of-io-biotech-inc-otc-iobtq-8dc91180ec7e42f2Pharma Surgeen2026-07-07T12:00:02.000ZEnterprise value to revenue forward of IO Biotech, Inc. – OTC:IOBTQhttps://www.pharmaradar360.com/article/tavneos-avacopan-and-health-canada-s-review-of-data-integrity-concerns-8bc4d1504481839fPharma Surgeen2026-07-07T12:00:00.000ZTAVNEOS (avacopan) and Health Canada’s Review of Data Integrity Concernshttps://www.pharmaradar360.com/article/theriva-wins-spain-nod-for-more-frequent-vcn-01-dosing-in-pancreatic-cancer-tria-f1106efacf0a71e9Pharma Surgeen2026-07-07T12:00:00.000ZTheriva wins Spain nod for more frequent VCN-01 dosing in pancreatic cancer trialhttps://www.pharmaradar360.com/article/vivani-medical-enters-into-agreement-with-novo-nordisk-to-evaluate-npm-139-a-min-70d84d711f698d62Pharma Surgeen2026-07-07T11:35:00.000ZVivani Medical Enters into Agreement with Novo Nordisk to Evaluate NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Managementhttps://www.pharmaradar360.com/article/this-biotech-stock-is-soaring-99-after-vertex-agrees-to-takeover-deal-f2b00cb4fc552de5Pharma Surgeen2026-07-07T11:33:00.000ZThis Biotech Stock Is Soaring 99% After Vertex Agrees to Takeover Dealhttps://www.pharmaradar360.com/article/dear-doctor-is-it-true-pharmaceutical-companies-are-suppressing-peptides-because-dc224bc8bee92912Pharma Surgeen2026-07-07T11:30:00.000ZDear Doctor: Is it true pharmaceutical companies are suppressing peptides because of competition?https://www.pharmaradar360.com/article/kailera-therapeutics-announces-positive-topline-data-from-two-hengrui-pharma-pha-e9f2635fadac0d24Pharma Surgeen2026-07-07T11:22:31.000ZKailera Therapeutics Announces Positive Topline Data from Two Hengrui Pharma Phase 3 Clinical Trials of Oral Small Molecule GLP-1 Receptor Agonist HRS-7535/KAI-7535https://www.pharmaradar360.com/article/annovis-reaches-full-enrollment-in-pivotal-phase-3-trial-of-buntanetap-for-early-a25ac20f1d365251Pharma Surgeen2026-07-07T11:22:21.000ZAnnovis Reaches Full Enrollment in Pivotal Phase 3 Trial of Buntanetap for Early Alzheimer’s Diseasehttps://www.pharmaradar360.com/article/axsome-therapeutics-initiates-focus-2-phase-3-trial-of-solriamfetol-in-children-0840e43a096faefePharma Surgeen2026-07-07T11:22:08.000ZAxsome Therapeutics Initiates FOCUS-2 Phase 3 Trial of Solriamfetol in Children with Attention Deficit Hyperactivity Disorder (ADHD)https://www.pharmaradar360.com/article/field-safety-notices-29-june-to-03-july-2026-f51c6e309cfc832ePharma Surgeen2026-07-07T11:14:05.000ZField Safety Notices: 29 June to 03 July 2026https://www.pharmaradar360.com/article/what-do-i-need-to-know-about-daraxonrasib-the-new-treatment-for-pancreatic-cance-6b36c4a5afd43e73Pharma Surgeen2026-07-07T11:09:30.000ZWhat do I need to know about daraxonrasib, the new treatment for pancreatic cancer?https://www.pharmaradar360.com/article/fda-backs-single-phase-3-trial-for-alterity-s-msa-drug-ath434-5f6f015a20e0b674Pharma Surgeen2026-07-07T11:05:00.000ZFDA backs single Phase 3 trial for Alterity’s MSA drug ATH434https://www.pharmaradar360.com/article/axsome-starts-phase-3-adhd-trial-in-children-enrolling-468-patients-6a6061d761fd5388Pharma Surgeen2026-07-07T11:00:00.000ZAxsome starts Phase 3 ADHD trial in children, enrolling 468 patientshttps://www.pharmaradar360.com/article/annovis-enrolls-850-patients-in-phase-3-alzheimer-s-study-0771ac8bbf58adc0Pharma Surgeen2026-07-07T11:00:00.000ZAnnovis enrolls 850 patients in Phase 3 Alzheimer’s studyhttps://www.pharmaradar360.com/article/kailera-therapeutics-announces-positive-topline-data-from-two-hengrui-pharma-pha-47f47641776a4e99Pharma Surgeen2026-07-07T11:00:00.000ZKailera Therapeutics Announces Positive Topline Data from Two Hengrui Pharma Phase 3 Clinical Trials of Oral Small Molecule GLP-1 Receptor Agonist HRS-7535/KAI-7535https://www.pharmaradar360.com/article/annovis-reaches-full-enrollment-in-pivotal-phase-3-trial-of-buntanetap-for-early-66d4f99c8ab8984aPharma Surgeen2026-07-07T11:00:00.000ZAnnovis Reaches Full Enrollment in Pivotal Phase 3 Trial of Buntanetap for Early Alzheimer’s Diseasehttps://www.pharmaradar360.com/article/dhsc-spending-over-25-000-12432027a49613e7Pharma Surgeen2026-07-07T10:58:45.000ZDHSC spending over £25,000https://www.pharmaradar360.com/article/shanghai-hong-kong-bootcamp-selects-ai-and-biotech-projects-3f642eeea2ab252dPharma Surgeen2026-07-07T10:58:43.000ZShanghai-Hong Kong Bootcamp Selects AI and Biotech Projectshttps://www.pharmaradar360.com/article/dhsc-spending-over-25-000-february-2026-b20ca4cb325bef21Pharma Surgeen2026-07-07T10:58:06.000ZDHSC: spending over £25,000, February 2026https://www.pharmaradar360.com/article/brandon-capital-scores-its-biggest-return-ever-with-2-1bn-biotech-acquisition-426c1053b54c6ee8Pharma Surgeen2026-07-07T10:34:17.000ZBrandon Capital scores its biggest return ever with $2.1bn biotech acquisitionhttps://www.pharmaradar360.com/article/rcs-intnl-biotechnology-portfolio-company-crinetics-acquired-by-vertex-3607d0b29e43fdcdPharma Surgeen2026-07-07T10:34:02.000ZRCS - Intnl. Biotechnology - Portfolio company Crinetics acquired by Vertexhttps://www.pharmaradar360.com/article/decision-advertising-investigations-june-2026-a316cedf64c3ced3Pharma Surgeen2026-07-07T10:30:42.000ZDecision: Advertising investigations: June 2026https://www.pharmaradar360.com/article/decision-orphan-registered-medicinal-products-1895e594079472ebPharma Surgeen2026-07-07T10:30:12.000ZDecision: Orphan registered medicinal productshttps://www.pharmaradar360.com/article/compass-pathways-says-second-psilocybin-trial-kept-depression-benefit-for-6-mont-6b2f2d329a20da71Pharma Surgeen2026-07-07T10:30:00.000ZCompass Pathways says second psilocybin trial kept depression benefit for 6 monthshttps://www.pharmaradar360.com/article/compass-pathways-announces-six-month-data-from-second-phase-3-trial-confirming-r-273b8261b66b5a2dPharma Surgeen2026-07-07T10:30:00.000ZCompass Pathways Announces Six-Month Data from Second Phase 3 Trial Confirming Rapid and Durable Profilehttps://www.pharmaradar360.com/article/the-changing-reality-of-pharmaceutical-commercialization-in-a-cold-chain-driven-bb4990ff8d52755dPharma Surgeen2026-07-07T10:10:16.000ZThe Changing Reality of Pharmaceutical Commercialization in a Cold Chain-Driven Markethttps://www.pharmaradar360.com/article/ono-pharmaceutical-co-ophlf-moves-10-4-higher-will-this-strength-last-1598343eed217249Pharma Surgeen2026-07-07T10:08:00.000ZOno Pharmaceutical Co. (OPHLF) Moves 10.4% Higher: Will This Strength Last?https://www.pharmaradar360.com/article/cmg-pharmaceutical-co-ltd-announced-that-it-has-received-krw-45-billion-in-fundi-8762af8d7552bd85Pharma Surgeen2026-07-07T10:05:40.000ZCMG Pharmaceutical Co., Ltd. announced that it has received KRW 45 billion in funding from Korea Investment & Securities Co., Ltd.https://www.pharmaradar360.com/article/fda-outlines-single-phase-3-trial-plan-for-alterity-nasdaq-athe-ath434-e22cfc4168b03803Pharma Surgeen2026-07-07T10:04:06.000ZFDA outlines single Phase 3 trial plan for Alterity (NASDAQ: ATHE) ATH434https://www.pharmaradar360.com/article/uk-biotechs-struggling-to-access-finance-as-scale-up-concerns-grow-f52d1d5556bb95f0Pharma Surgeen2026-07-07T10:00:48.000ZUK biotechs struggling to access finance as scale-up concerns growhttps://www.pharmaradar360.com/article/west-to-host-second-quarter-2026-conference-call-c1f1a3d6d5ebf729Pharma Surgeen2026-07-07T10:00:00.000ZWest to Host Second-Quarter 2026 Conference Callhttps://www.pharmaradar360.com/article/why-maharashtra-fda-banned-compulsory-hospital-pharmacy-purchases-b98794707a5a1a06Pharma Surgeen2026-07-07T09:46:36.000ZWhy Maharashtra FDA Banned Compulsory Hospital Pharmacy Purchaseshttps://www.pharmaradar360.com/article/how-do-analysts-rate-this-biotech-focused-on-chronic-inflammatory-diseases-f520bec606c17ccdPharma Surgeen2026-07-07T09:42:03.000ZHow Do Analysts Rate This Biotech Focused on Chronic Inflammatory Diseases?https://www.pharmaradar360.com/article/french-clinical-stage-biotech-s-uc-drug-faces-best-in-disease-doubts-as-analyst-d86c752ba559c435Pharma Surgeen2026-07-07T09:42:03.000ZFrench Clinical-Stage Biotech's UC Drug Faces 'Best in Disease' Doubts as Analyst Lifts Target Ahead of 4Q26 FDA Filinghttps://www.pharmaradar360.com/article/sanyou-and-baiyunshan-xihe-sign-radiopharma-deal-b033b4660a487d03Pharma Surgeen2026-07-07T09:32:13.000ZSanyou and Baiyunshan Xihe sign radiopharma dealhttps://www.pharmaradar360.com/article/krazati-combo-misses-phase-iii-mark-in-colorectal-cancer-cf58bcd7ad2bf903Pharma Surgeen2026-07-07T09:32:13.000ZKrazati combo misses Phase III mark in colorectal cancerhttps://www.pharmaradar360.com/article/rare-japan-ip-court-opinion-request-probes-pharmaceutical-patent-rules-67d7f48bc86addcbPharma Surgeen2026-07-07T09:12:00.000ZRare Japan IP Court opinion request probes pharmaceutical patent ruleshttps://www.pharmaradar360.com/article/working-for-dhsc-7fde6c0568507ce7Pharma Surgeen2026-07-07T09:10:38.000ZWorking for DHSChttps://www.pharmaradar360.com/article/rotavirus-vaccination-programme-information-for-healthcare-practitioners-53785302d776c5f3Pharma Surgeen2026-07-07T09:02:11.000ZRotavirus vaccination programme: information for healthcare practitionershttps://www.pharmaradar360.com/article/cereno-scientific-completes-all-dosing-and-participant-visits-in-cs014-s-fda-ali-c871d670a450d89dPharma Surgeen2026-07-07T09:00:00.000ZCereno Scientific Completes All Dosing and Participant Visits in CS014’s FDA-Aligned PK-Bridging Study, Advancing Capital-Efficient Path Toward Phase IIb in PH-ILDhttps://www.pharmaradar360.com/article/uk-clinical-research-delivery-key-performance-indicators-data-to-july-2026-5cb6f6902269e1ecPharma Surgeen2026-07-07T08:43:44.000ZUK Clinical Research Delivery key performance indicators: data to July 2026https://www.pharmaradar360.com/article/woodberry-packaging-acquires-medica-and-curtis-strengthening-its-position-in-pha-8078b9fe1ab6d86ePharma Surgeen2026-07-07T08:40:23.000ZWoodberry Packaging acquires Medica and Curtis, strengthening its position in pharmaceutical and personal care packaginghttps://www.pharmaradar360.com/article/medicine-supply-disruption-statistics-uk-data-to-june-2026-5ce9d540fae1527cPharma Surgeen2026-07-07T08:40:01.000ZMedicine supply disruption statistics, UK: data to June 2026https://www.pharmaradar360.com/article/uk-clinical-research-delivery-key-performance-indicators-data-to-june-2026-95407ca4abeca4e9Pharma Surgeen2026-07-07T08:38:01.000ZUK Clinical Research Delivery key performance indicators: data to June 2026https://www.pharmaradar360.com/article/polio-global-eradication-nac-and-environmental-surveillance-28a88d7a1d6b4d94Pharma Surgeen2026-07-07T08:34:51.000ZPolio: global eradication, NAC and environmental surveillancehttps://www.pharmaradar360.com/article/2026-b7f2bfa19e6fb750Pharma Surgeen2026-07-07T08:31:22.000ZΕπιστημονικές εκδηλώσεις εσωτερικού Α΄ εξαμήνου 2026https://www.pharmaradar360.com/article/guidance-clinical-trials-for-medicines-roles-and-responsibilities-3e0684843843bbdcPharma Surgeen2026-07-07T08:23:12.000ZGuidance: Clinical trials for medicines: roles and responsibilitieshttps://www.pharmaradar360.com/article/as-ai-sectors-cooldown-biotech-breaks-out-6-stocks-quietly-outperform-feeb27629042d7bcPharma Surgeen2026-07-07T08:20:26.000ZAs AI Sectors Cooldown, BioTech Breaks Out: 6 Stocks Quietly Outperformhttps://www.pharmaradar360.com/article/biotech-layoffs-in-2026-trends-triggers-and-what-s-at-stake-7c47efcd2cd6ebbePharma Surgeen2026-07-07T08:17:47.000ZBiotech Layoffs in 2026: Trends, Triggers, and What’s at Stakehttps://www.pharmaradar360.com/article/decision-doxecitine-and-doxribtimine-in-the-treatment-of-thymidine-kinase-2-defi-98729cfb4ffb37fcPharma Surgeen2026-07-07T08:15:25.000ZDecision: Doxecitine and Doxribtimine in the treatment of thymidine kinase 2 deficiency (TK2d)https://www.pharmaradar360.com/article/why-customer-experience-centers-are-becoming-practical-infrastructure-for-life-s-18f4fb049a82176cPharma Surgeen2026-07-07T08:03:44.000ZWhy Customer Experience Centers are becoming practical infrastructure for life sciences innovation in Europehttps://www.pharmaradar360.com/article/your-medicine-bottle-is-getting-a-qr-code-and-it-could-actually-save-your-life-6899e9309924dedaPharma Surgeen2026-07-07T08:00:14.000ZYour Medicine Bottle Is Getting a QR Code — and It Could Actually Save Your Lifehttps://www.pharmaradar360.com/article/biovica-expands-master-services-agreement-with-a-current-customer-a-leading-glob-60d72aa05adb38a7Pharma Surgeen2026-07-07T08:00:00.000ZBiovica expands Master Services Agreement with a current customer, a leading global pharmaceutical company, to support next-generation oncology development.https://www.pharmaradar360.com/article/abl-bio-targets-december-phase-3-start-for-abl111-in-gastric-cancer-cab24dfeb858d0bfPharma Surgeen2026-07-07T07:43:37.000ZABL Bio targets December phase 3 start for ABL111 in gastric cancerhttps://www.pharmaradar360.com/article/korean-nf2-drug-candidate-trineumin-wins-fda-rare-pediatric-disease-designation-f49644b6fd0506d0Pharma Surgeen2026-07-07T07:43:14.000ZKorean NF2 drug candidate Trineumin wins FDA rare pediatric disease designationhttps://www.pharmaradar360.com/article/hospitals-forcing-exclusive-prescriptions-now-on-fda-s-radar-says-tukaram-mundhe-579b7a0f0c99c9b0Pharma Surgeen2026-07-07T07:38:39.000ZHospitals Forcing Exclusive Prescriptions Now On FDA's Radar, Says Tukaram Mundhehttps://www.pharmaradar360.com/article/abl-bio-to-begin-phase-3-clinical-trial-of-abl111-in-december-sanofi-risks-also-d76a7c05cc7e4000Pharma Surgeen2026-07-07T07:18:06.000ZABL Bio to Begin Phase 3 Clinical Trial of 'ABL111' in December... Sanofi Risks Also Resolvedhttps://www.pharmaradar360.com/article/price-to-book-forward-of-jiangsu-cowin-biotech-co-ltd-class-a-sse-688426-22ac643d1b24eb05Pharma Surgeen2026-07-07T07:09:54.000ZPrice to book forward of Jiangsu Cowin Biotech Co., Ltd. Class A – SSE:688426https://www.pharmaradar360.com/article/sustained-release-polymers-market-advances-as-drug-delivery-innovation-reshapes-3cf8b187703c91e1Pharma Surgeen2026-07-07T07:01:55.000ZSustained Release Polymers Market Advances as Drug Delivery Innovation Reshapes Pharmaceutical Formulation Strategies with USD 7.8 Billion in 2036 | Future Market Insightshttps://www.pharmaradar360.com/article/abl-bio-pursues-big-pharma-deals-as-korea-advances-cancer-and-bbb-programs-chosu-4369581b0888c6b6Pharma Surgeen2026-07-07T06:59:00.000ZABL Bio pursues big pharma deals as Korea advances cancer and BBB programs - CHOSUNBIZhttps://www.pharmaradar360.com/article/samjin-pharm-launches-fulvestrant-injection-for-hr-her2-advanced-breast-cancer-55738b181e40e3efPharma Surgeen2026-07-07T06:42:09.000ZSamjin Pharm launches fulvestrant injection for HR+/HER2- advanced breast cancerhttps://www.pharmaradar360.com/article/italy-s-angels-incubators-and-venture-capital-weekly-roundup-news-from-banyan-bi-4cfd345637eec390Pharma Surgeen2026-07-07T06:31:06.000ZItaly’s angels & incubators and venture capital weekly roundup. News from Banyan Biotech, Berrier Capital and morehttps://www.pharmaradar360.com/article/french-gene-therapy-biotech-gets-33m-to-follow-krystal-s-blueprint-c63e060b6fd86bd4Pharma Surgeen2026-07-07T05:30:00.000ZFrench gene therapy biotech gets €33M to follow Krystal’s blueprinthttps://www.pharmaradar360.com/article/hc-questions-fda-push-to-invoke-mcoca-in-food-safety-cases-across-maha-6bbd93fbb79cdc4fPharma Surgeen2026-07-07T05:15:00.000ZHC questions FDA push to invoke MCOCA in food safety cases across Mahahttps://www.pharmaradar360.com/article/hc-questions-fda-push-to-invoke-mcoca-in-food-safety-cases-across-maha-46dc70bdb7397099Pharma Surgeen2026-07-07T05:07:02.000ZHC questions FDA push to invoke MCOCA in food safety cases across Mahahttps://www.pharmaradar360.com/article/gc-biopharma-wins-approval-for-domestic-phase-3-clinical-trial-of-two-dose-varic-a34fb9abe6db1443Pharma Surgeen2026-07-07T05:06:44.000ZGC Biopharma wins approval for domestic Phase 3 clinical trial of two-dose varicella vaccinehttps://www.pharmaradar360.com/article/drug-discovery-ai-moves-beyond-hype-to-an-r-d-productivity-test-578841b8458cb71bPharma Surgeen2026-07-07T05:02:25.000ZDrug discovery AI moves beyond hype to an R&D productivity testhttps://www.pharmaradar360.com/article/roche-presents-new-data-in-alzheimer-s-disease-from-across-its-integrated-pharma-859cacd0e13dbf48Pharma Surgeen2026-07-07T05:00:00.000ZRoche presents new data in Alzheimer’s disease from across its integrated pharmaceutical and diagnostics portfolio at AAIChttps://www.pharmaradar360.com/article/roche-presents-new-data-in-alzheimer-s-disease-from-across-its-integrated-pharma-f051c2312acd4eb2Pharma Surgeen2026-07-07T05:00:00.000ZRoche presents new data in Alzheimer’s disease from across its integrated pharmaceutical and diagnostics portfolio at AAIChttps://www.pharmaradar360.com/article/us-fda-confirms-alterity-s-phase-iii-trial-path-b6a08f225b300d0fPharma Surgeen2026-07-07T04:58:00.000ZUS FDA confirms Alterity’s Phase III trial pathhttps://www.pharmaradar360.com/article/the-clinical-trial-that-supported-tavneos-for-anca-vasculitis-was-just-retracted-b08c08b64d438a01Pharma Surgeen2026-07-07T04:54:42.000ZThe Clinical Trial That Supported Tavneos for ANCA Vasculitis Was Just Retractedhttps://www.pharmaradar360.com/article/drug-discovery-ai-moves-beyond-hype-to-an-r-d-productivity-test-de399667f7a3b694Pharma Surgeen2026-07-07T04:43:32.000ZDrug discovery AI moves beyond hype to an R&D productivity testhttps://www.pharmaradar360.com/article/price-to-earnings-forward-of-pci-biotech-holding-asa-ls-a0q2fs-39085cc0e3b2325bPharma Surgeen2026-07-07T04:25:35.000ZPrice to earnings forward of PCI Biotech Holding ASA – LS:A0Q2FShttps://www.pharmaradar360.com/article/matica-biotech-vaxdome-partner-to-advance-antiviral-vaccine-platform-into-clinic-1b8321a66b6e0a87Pharma Surgeen2026-07-07T04:03:43.000ZMatica Biotech, VaxDome partner to advance antiviral vaccine platform into clinichttps://www.pharmaradar360.com/article/fda-warns-of-fatal-liver-injuries-tied-to-drug-it-wants-pulled-from-market-8e7a5fdd0872d3a2Pharma Surgeen2026-07-07T04:02:58.000ZFDA warns of fatal liver injuries tied to drug it wants pulled from markethttps://www.pharmaradar360.com/article/glp-1-receptor-agonist-exposures-reported-to-poison-center-up-after-fda-approval-0c0be06290ebcdaePharma Surgeen2026-07-07T04:00:00.000ZGLP-1 Receptor Agonist Exposures Reported to Poison Center Up After FDA Approval for Weight Losshttps://www.pharmaradar360.com/article/vertex-signs-letter-of-intent-loi-with-the-pan-canadian-pharmaceutical-alliance-32248ff88480cc43Pharma Surgeen2026-07-07T03:47:20.000ZVertex Signs Letter of Intent (LOI) with the pan-Canadian Pharmaceutical Alliance for ALYFTREK for the Treatment of Cystic Fibrosishttps://www.pharmaradar360.com/article/three-biotech-stocks-crushed-the-s-p-500-analysts-still-back-just-one-1cf415a0b004cc3ePharma Surgeen2026-07-07T03:32:34.000ZThree Biotech Stocks Crushed the S&P 500 — Analysts Still Back Just Onehttps://www.pharmaradar360.com/article/texas-pushes-forward-with-state-ibogaine-research-program-after-failing-to-find-4ae613fb9cd76c18Pharma Surgeen2026-07-07T03:11:00.000ZTexas pushes forward with state ibogaine research program after failing to find drug company partnerhttps://www.pharmaradar360.com/article/aribio-to-unveil-new-ar1001-data-at-alzheimer-s-conference-998851679b5c101bPharma Surgeen2026-07-07T03:05:29.000ZAriBio to unveil new AR1001 data at Alzheimer's conferencehttps://www.pharmaradar360.com/article/alterity-therapeutics-clears-key-fda-hurdle-for-ath434-phase-3-pathway-7241ff566c6d5df4Pharma Surgeen2026-07-07T03:03:41.000ZAlterity Therapeutics clears key FDA hurdle for ATH434 Phase 3 pathwayhttps://www.pharmaradar360.com/article/anzen-mhlw-pharmaceuticals-and-medical-devices-safety-information-no-429-posted-d1435f2c2e88bb2fPharma Surgeen2026-07-07T03:00:00.000Z[ANZEN]MHLW Pharmaceuticals and Medical Devices Safety Information No.429 postedhttps://www.pharmaradar360.com/article/china-s-national-medical-products-administration-accepts-biologics-license-appli-00dae1ff100e152fPharma Surgeen2026-07-07T02:30:00.000ZChina’s National Medical Products Administration Accepts Biologics License Application for PADCEV™ (enfortumab vedotin) plus Keytruda® (pembrolizumab) in Muscle-Invasive Bladder Cancerhttps://www.pharmaradar360.com/article/belite-bio-blte-after-new-phase-3-data-news-and-the-case-for-fair-value-1f609f0996a22856Pharma Surgeen2026-07-07T01:34:36.000ZBelite Bio (BLTE) After New Phase 3 Data News And The Case For Fair Valuehttps://www.pharmaradar360.com/article/us-based-malayali-carves-a-niche-with-knee-treatment-255854012aa5998cPharma Surgeen2026-07-07T01:30:39.000ZUS-based Malayali carves a niche with knee treatmenthttps://www.pharmaradar360.com/article/sarepta-announces-fda-acceptance-of-sndas-for-amondys-45-and-vyondys-53-7be94b2b54c2f9d1Pharma Surgeen2026-07-07T00:52:31.000ZSarepta Announces FDA Acceptance of sNDAs for AMONDYS 45® and VYONDYS 53®https://www.pharmaradar360.com/article/vertex-pharmaceuticals-filed-form-8-k-7c7fb8b633423119Pharma Surgeen2026-07-07T00:00:00.000ZVertex Pharmaceuticals filed Form 8-Khttps://www.pharmaradar360.com/article/sanofi-filed-form-6-k-6eefe1e61c1295bdPharma Surgeen2026-07-07T00:00:00.000ZSanofi filed Form 6-Khttps://www.pharmaradar360.com/article/new-technologies-could-help-cut-years-long-wait-for-endometriosis-diagnosis-says-528e4e37e26bada6Pharma Surgeen2026-07-07T00:00:00.000ZNew technologies could help cut years-long wait for endometriosis diagnosis, says NICEhttps://www.pharmaradar360.com/article/view-all-news-articles-c59e11b18e2ad94dPharma Surgeen2026-07-07T00:00:00.000ZView all news articleshttps://www.pharmaradar360.com/article/natco-records-e2-82-b9816-9-crore-consolidated-revenue-and-e2-82-b9269-0-crore-o-c4dd42ede001d623Pharma Surgeen2026-07-07T00:00:00.000Znatco records %e2%82%b9816 9 crore consolidated revenue and %e2%82%b9269 0 crore of profit after tax for q4 fy26 and %e2%82%b94375 9 crore of revenue %e2%82%b91418 5 crore profit after tax for fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b9705-4-crore-consolidated-revenue-and-e2-82-b9151-3-crore-o-dc70e319325b088ePharma Surgeen2026-07-07T00:00:00.000Znatco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b91463-crore-consolidated-revenue-and-e2-82-b9517-9-crore-of-06a27c44871a176dPharma Surgeen2026-07-07T00:00:00.000Znatco records %e2%82%b91463 crore consolidated revenue and %e2%82%b9517 9 crore of profit after tax for q2fy26https://www.pharmaradar360.com/article/natco-receives-tentative-approval-for-erdafitinib-tablets-generic-of-balversa-fr-dfd763ce0e2e3295Pharma Surgeen2026-07-07T00:00:00.000Znatco receives tentative approval for erdafitinib tablets generic of balversa from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/natco-receives-approval-from-central-drug-standard-control-organisation-cdsco-fo-864ce3400be36cb1Pharma Surgeen2026-07-07T00:00:00.000Znatco receives approval from central drug standard control organisation cdsco for semaglutide in indiahttps://www.pharmaradar360.com/article/natco-pharma-limited-api-unit-in-chennai-receives-establishment-inspection-repor-f2ec82ff27baa71ePharma Surgeen2026-07-07T00:00:00.000Znatco pharma limited api unit in chennai receives establishment inspection report eir from u s fdahttps://www.pharmaradar360.com/article/natco-pharma-launches-semaglutide-generic-injection-multi-dose-vials-in-india-at-8c91b2243be6e6ecPharma Surgeen2026-07-07T00:00:00.000Znatco pharma launches semaglutide generic injection multi dose vials in india at the most affordable price starting from mrp inr 1290https://www.pharmaradar360.com/article/natco-announces-launch-of-pomalidomide-capsules-generic-of-pomalyst-in-the-u-s-m-5597743969d29c98Pharma Surgeen2026-07-07T00:00:00.000Znatco announces launch of pomalidomide capsules generic of pomalyst in the u s markethttps://www.pharmaradar360.com/article/natco-announces-launch-of-its-everolimus-tablets-1-mg-generic-of-zortress-386e4a075c34ba1dPharma Surgeen2026-07-07T00:00:00.000Znatco announces launch of its everolimus tablets 1 mg generic of zortresshttps://www.pharmaradar360.com/article/natco-and-lupin-receive-approval-from-u-s-fda-for-eribulin-mesylate-injection-9ed385263e2bfabcPharma Surgeen2026-07-07T00:00:00.000Znatco and lupin receive approval from u s fda for eribulin mesylate injectionhttps://www.pharmaradar360.com/article/intimation-under-regulation-30-of-sebi-listing-obligations-and-disclosure-requir-a99946acfb034930Pharma Surgeen2026-07-07T00:00:00.000Zintimation under regulation 30 of sebi listing obligations and disclosure requirements regulations 2015 2https://www.pharmaradar360.com/article/disclosure-under-regulation-30-of-the-sebi-listing-obligations-and-disclosure-re-11f10f6ad40e67d5Pharma Surgeen2026-07-07T00:00:00.000Zdisclosure under regulation 30 of the sebi listing obligations and disclosure requirements regulations 2015https://www.pharmaradar360.com/article/adcock-ingram-completes-delisting-from-jse-natco-pharma-acquires-35-75-stake-86ea2faa398ce787Pharma Surgeen2026-07-07T00:00:00.000Zadcock ingram completes delisting from jse natco pharma acquires 35 75 stakehttps://www.pharmaradar360.com/article/home-page-7db9b76e6be24d82Pharma Surgeen2026-07-07T00:00:00.000ZHome pagehttps://www.pharmaradar360.com/article/new-animal-drugs-approval-of-new-animal-drug-applications-withdrawal-of-approval-fec0647368369f3aPharma Surgeen2026-07-07T00:00:00.000ZNew Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of Sponsorhttps://www.pharmaradar360.com/article/office-of-the-secretary-notice-of-meeting-c0ba619840c46db4Pharma Surgeen2026-07-07T00:00:00.000ZOffice of the Secretary; Notice of Meetinghttps://www.pharmaradar360.com/article/recission-of-the-national-cancer-institute-clinical-cancer-education-program-reg-be11376bf7623390Pharma Surgeen2026-07-07T00:00:00.000ZRecission of the National Cancer Institute Clinical Cancer Education Program Regulationhttps://www.pharmaradar360.com/article/importer-of-controlled-substances-application-benuvia-operations-llc-d13da85284e18846Pharma Surgeen2026-07-07T00:00:00.000ZImporter of Controlled Substances Application: Benuvia Operations, LLC.https://www.pharmaradar360.com/article/center-for-scientific-review-notice-of-closed-meetings-7de317d9222efac3Pharma Surgeen2026-07-07T00:00:00.000ZCenter for Scientific Review; Notice of Closed Meetingshttps://www.pharmaradar360.com/article/privacy-act-of-1974-matching-program-00497debdfd6bcd2Pharma Surgeen2026-07-07T00:00:00.000ZPrivacy Act of 1974; Matching Programhttps://www.pharmaradar360.com/article/medicare-program-hospital-outpatient-prospective-payment-and-ambulatory-surgical-3c67d0de69b46fa0Pharma Surgeen2026-07-07T00:00:00.000ZMedicare Program: Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems; and Quality Reporting Programs; Including the Hospital Outpatient Quality Reporting Program and Ambulatory Surgical Center Quality Program; Request for Information on Strengthening the Standardihttps://www.pharmaradar360.com/article/agency-information-collection-activities-submission-to-omb-for-review-and-approv-ee8f225175e0aad8Pharma Surgeen2026-07-07T00:00:00.000ZAgency Information Collection Activities: Submission to OMB for Review and Approval; Public Comment Request; Rural Health Care Services Outreach Program Measures, OMB No. 0906-0009-Revisionhttps://www.pharmaradar360.com/article/national-institute-of-diabetes-and-digestive-and-kidney-diseases-amended-notice-230aa57d07ee67a4Pharma Surgeen2026-07-07T00:00:00.000ZNational Institute of Diabetes and Digestive and Kidney Diseases; Amended Notice of Meetinghttps://www.pharmaradar360.com/article/cleveland-clinic-expanding-saturday-surgery-and-procedure-offerings-1cb0a73898abd437Pharma Surgeen2026-07-07T00:00:00.000ZCleveland Clinic Expanding Saturday Surgery and Procedure Offeringshttps://www.pharmaradar360.com/article/bausch-health-to-announce-second-quarter-2026-results-on-july-29-2026-6e0717d6818ce297Pharma Surgeen2026-07-07T00:00:00.000ZBausch Health to Announce Second Quarter 2026 Results on July 29, 2026https://www.pharmaradar360.com/article/patient-centered-prescription-opioid-tapering-methods-280a7f0f0db1e533Pharma Surgeen2026-07-07T00:00:00.000ZPatient-Centered Prescription Opioid Tapering Methodshttps://www.pharmaradar360.com/article/assessment-of-an-educational-intervention-for-embryologists-to-reduce-gamete-and-79626f280681eeb1Pharma Surgeen2026-07-07T00:00:00.000ZAssessment of an educational intervention for embryologists to reduce gamete and embryo misidentification in <i>in vitro</i> fertilization laboratorieshttps://www.pharmaradar360.com/article/peer-review-report-for-barriers-and-facilitators-to-interprofessional-work-in-cl-7825d4ea1854c9fbPharma Surgeen2026-07-07T00:00:00.000ZPeer Review Report For: Barriers and Facilitators to Interprofessional Work in Clinical Settings in Japan: A Systematic Review of Qualitative Research [version 1; peer review: 1 approved with reservations]https://www.pharmaradar360.com/article/outcomes-of-liver-transplantation-in-critically-ill-patients-admitted-to-an-inte-5ab747d8797fda48Pharma Surgeen2026-07-07T00:00:00.000ZOutcomes of liver transplantation in critically ill patients admitted to an intensive care unit: a retrospective studyhttps://www.pharmaradar360.com/article/comparative-study-of-recovery-characteristics-between-remimazolam-anesthesia-wit-00f164b754232019Pharma Surgeen2026-07-07T00:00:00.000ZComparative study of recovery characteristics between remimazolam anesthesia with flumazenil and desflurane anesthesia for closed reduction of nasal bone fracture: a randomized controlled trialhttps://www.pharmaradar360.com/article/antithrombotic-therapy-after-percutaneous-closure-of-paravalvular-leaks-patterns-ccd0eaf8f5f75fa1Pharma Surgeen2026-07-07T00:00:00.000ZAntithrombotic therapy after percutaneous closure of paravalvular leaks: Patterns of use and clinical outcomes in a single-center retrospective registryhttps://www.pharmaradar360.com/article/detection-of-mycobacterium-tuberculosis-complex-and-differentiation-of-five-comm-70861d531e346985Pharma Surgeen2026-07-07T00:00:00.000ZDetection of Mycobacterium tuberculosis Complex and Differentiation of Five Common Nontuberculous Mycobacteria Directly from Clinical Specimens Using a Multiplex PCR Assayhttps://www.pharmaradar360.com/article/a-new-severity-index-for-placental-abruption-predicts-recurrence-risk-in-future-116109386f6a46a5Pharma Surgeen2026-07-07T00:00:00.000ZA New Severity Index for Placental Abruption Predicts Recurrence Risk in Future Pregnancieshttps://www.pharmaradar360.com/article/association-between-gastroesophageal-reflux-symptoms-and-temporomandibular-disor-3e6067f5c26c4b8dPharma Surgeen2026-07-07T00:00:00.000ZAssociation Between Gastroesophageal Reflux Symptoms and Temporomandibular Disorders in Healthcare Professionals: The Role of Shift Work, Oral Parafunctions, and Psychological Distresshttps://www.pharmaradar360.com/article/effects-of-sglt2-inhibitors-on-proteinuria-and-renal-function-parameters-in-non-7aa9d7b72c46edadPharma Surgeen2026-07-07T00:00:00.000ZEffects of SGLT2 Inhibitors on Proteinuria and Renal Function Parameters in Non-Diabetic Kidney Transplant Recipients: A Retrospective Cohort Study Based on 12-Month Follow-Up Datahttps://www.pharmaradar360.com/article/early-post-transplant-changes-in-nutritional-status-predict-long-term-graft-loss-b365edcc2ea73793Pharma Surgeen2026-07-07T00:00:00.000ZEarly Post-Transplant Changes in Nutritional Status Predict Long-Term Graft Loss and Mortalityhttps://www.pharmaradar360.com/article/clinical-effect-evaluation-of-postoperative-complications-of-papillary-thyroid-c-e15681e655064329Pharma Surgeen2026-07-07T00:00:00.000ZClinical effect evaluation of postoperative complications of papillary thyroid carcinoma based on individualized intervention and prognostic analysis of precision nursing interventionhttps://www.pharmaradar360.com/article/lower-limb-rehabilitation-in-chronic-incomplete-sci-a-randomized-controlled-tria-08f26bc6c2d09e9fPharma Surgeen2026-07-07T00:00:00.000ZLower limb rehabilitation in chronic incomplete SCI: a randomized controlled trial protocol comparing combined TMS-tSCS neuromodulation vs. tSCS alonehttps://www.pharmaradar360.com/article/efficacy-of-tuina-combined-with-core-stability-training-on-lumbar-stability-and-bdb6a3716e71c6abPharma Surgeen2026-07-07T00:00:00.000ZEfficacy of Tuina combined with core stability training on lumbar stability and clinical outcomes in patients with lumbar disc herniation: a randomized controlled trial protocolhttps://www.pharmaradar360.com/article/clinical-mapps-a-personalized-healthcare-driven-assay-for-the-direct-identificat-94940eb62df59486Pharma Surgeen2026-07-07T00:00:00.000ZClinical MAPPs: a personalized healthcare-driven assay for the direct identification of potential T cell epitopes in patientshttps://www.pharmaradar360.com/article/anti-gpiiia-antibody-and-cd4-count-identify-an-autoimmune-enriched-phenotype-of-ffaf98eca1537687Pharma Surgeen2026-07-07T00:00:00.000ZAnti-GPIIIa antibody and CD4 count identify an autoimmune-enriched phenotype of HIV-associated thrombocytopenia: development and internal validation of a clinical nomogramhttps://www.pharmaradar360.com/article/a-testable-framework-linking-diagnostic-ai-contribution-to-outcome-measurement-i-925c62d5faa817c3Pharma Surgeen2026-07-07T00:00:00.000ZA testable framework linking diagnostic AI contribution to outcome measurement in clinical decision supporthttps://www.pharmaradar360.com/article/molecular-mechanisms-and-targeted-interventions-for-embolic-risk-in-cardiac-myxo-75b0c4899d2a4f5ePharma Surgeen2026-07-07T00:00:00.000ZMolecular mechanisms and targeted interventions for embolic risk in cardiac myxoma: from molecular heterogeneity to clinical translationhttps://www.pharmaradar360.com/article/translational-research-in-drug-development-challenges-and-opportunities-for-phar-90687ef205ddc998Pharma Surgeen2026-07-07T00:00:00.000ZTranslational research in drug development: challenges and opportunities for pharmacistshttps://www.pharmaradar360.com/article/measuring-safety-risks-in-online-drug-sales-empirical-study-based-on-complex-net-e43fbce0095f9570Pharma Surgeen2026-07-07T00:00:00.000ZMeasuring Safety Risks in Online Drug Sales: Empirical Study Based on Complex Network Theoryhttps://www.pharmaradar360.com/article/psychological-disturbances-at-icu-discharge-evaluation-using-the-intensive-care-156185a60d61051ePharma Surgeen2026-07-07T00:00:00.000ZPsychological Disturbances at ICU Discharge: Evaluation Using the Intensive Care Psychological Assessment Tool (IPAT) and Association with Clinical Features: An observational cross-sectional studyhttps://www.pharmaradar360.com/article/clinical-equivalence-of-privacy-preserving-federated-learning-a-consortium-block-6812ebbf9b764ad3Pharma Surgeen2026-07-07T00:00:00.000ZClinical Equivalence of Privacy-Preserving Federated Learning: A Consortium Blockchain Framework with Equivalence Testinghttps://www.pharmaradar360.com/article/effects-of-smart-insole-based-ground-reaction-force-biofeedback-training-on-musc-5d795c14a492ae08Pharma Surgeen2026-07-07T00:00:00.000ZEffects of Smart Insole-Based Ground Reaction Force-Biofeedback Training on Muscle Strength, Balance in Patients with Strokehttps://www.pharmaradar360.com/article/the-spleen-negatively-regulates-the-acute-phase-of-experimental-autoimmune-encep-10ea362eca5dd100Pharma Surgeen2026-07-07T00:00:00.000ZThe Spleen Negatively Regulates the Acute Phase of Experimental Autoimmune Encephalomyelitis in Micehttps://www.pharmaradar360.com/article/optimizing-imatinib-sampling-strategies-through-a-population-approach-a-crucial-8ade5670abce53ebPharma Surgeen2026-07-07T00:00:00.000ZOptimizing imatinib sampling strategies through a population approach: a crucial step to model-informed precision dosing validation for point-of-care therapeutic drug monitoringhttps://www.pharmaradar360.com/article/mapping-the-safety-profile-of-histone-deacetylase-inhibitors-in-children-with-ca-48eb5a489fe067ecPharma Surgeen2026-07-07T00:00:00.000ZMapping the Safety Profile of Histone Deacetylase Inhibitors in Children with Cancerhttps://www.pharmaradar360.com/article/correction-unintentional-benzodiazepine-use-and-frequency-of-drug-checking-servi-fe31100f59e79e20Pharma Surgeen2026-07-07T00:00:00.000ZCorrection: Unintentional benzodiazepine use and frequency of drug checking service utilization: a cross-sectional studyhttps://www.pharmaradar360.com/article/kif23-in-disease-pathogenesis-and-therapeutics-from-molecular-mechanisms-to-clin-5b453eae8f3e4e20Pharma Surgeen2026-07-07T00:00:00.000ZKIF23 in disease pathogenesis and therapeutics : from molecular mechanisms to clinical translationhttps://www.pharmaradar360.com/article/caregiver-led-versus-therapist-led-training-programme-for-caregivers-of-children-0c4ff0982abe07c0Pharma Surgeen2026-07-07T00:00:00.000ZCaregiver-led versus therapist-led training programme for caregivers of children with cerebral palsy in rural Malawi: a feasibility randomised controlled trialhttps://www.pharmaradar360.com/article/a-randomized-clinical-trial-comparing-the-efficacy-of-probiotic-drops-and-sucros-4a9fd2306da89ff5Pharma Surgeen2026-07-07T00:00:00.000ZA randomized clinical trial comparing the efficacy of probiotic drops and sucrose in managing colic in early infancyhttps://www.pharmaradar360.com/article/retrospective-analysis-of-the-clinical-characteristics-of-childhood-ocular-traum-5e4e891cda7fb8e7Pharma Surgeen2026-07-07T00:00:00.000ZRetrospective analysis of the clinical characteristics of childhood ocular trauma, 2020–2024https://www.pharmaradar360.com/article/ferroptosis-and-sepsis-induced-myocardial-injury-a-prospective-clinical-study-225855bb538dac1bPharma Surgeen2026-07-07T00:00:00.000ZFerroptosis and sepsis-induced myocardial injury: a prospective clinical studyhttps://www.pharmaradar360.com/article/assessing-the-treatment-of-male-infertility-through-principal-component-analysis-3b6cde70a3bb71e4Pharma Surgeen2026-07-07T00:00:00.000ZAssessing the treatment of male infertility through principal component analysis: a retrospective studyhttps://www.pharmaradar360.com/article/evolocumab-in-patients-with-prior-percutaneous-coronary-intervention-and-no-prio-aecfcaf5110af478Pharma Surgeen2026-07-07T00:00:00.000ZEvolocumab in Patients With Prior Percutaneous Coronary Intervention and No Prior Myocardial Infarction: Results From the VESALIUS-CV Trialhttps://www.pharmaradar360.com/article/lifestyle-induced-visceral-fat-loss-as-a-key-target-for-durable-cardiometabolic-254b54946a0a1eabPharma Surgeen2026-07-07T00:00:00.000ZLifestyle-Induced Visceral Fat Loss as a Key Target for Durable Cardiometabolic Health: MRI-Assessed 5- and 10-Year Follow-Up After 2 Clinical Trialshttps://www.pharmaradar360.com/article/blinded-trial-of-multiplex-serodiagnostic-test-in-india-for-diverse-forms-of-act-00c377099ca7c442Pharma Surgeen2026-07-07T00:00:00.000ZBlinded trial of multiplex serodiagnostic test in India for diverse forms of active tuberculosishttps://www.pharmaradar360.com/article/family-functioning-and-medication-self-management-in-rural-older-adults-with-chr-6daae21099fa1b05Pharma Surgeen2026-07-07T00:00:00.000ZFamily Functioning and Medication Self‐Management in Rural Older Adults With Chronic Comorbidities: The Mediating Role of Self‐Efficacyhttps://www.pharmaradar360.com/article/divergent-radiomolecular-phenotype-of-spindle-cell-lipoma-b66237e7f6041d01Pharma Surgeen2026-07-07T00:00:00.000ZDivergent Radiomolecular Phenotype of Spindle Cell Lipoma​​​​​https://www.pharmaradar360.com/article/developmental-patterns-and-clinical-relevance-of-os-trigonum-os-subfibulare-and-387db09ad6c556eePharma Surgeen2026-07-07T00:00:00.000ZDevelopmental Patterns and Clinical Relevance of Os Trigonum, Os Subfibulare, and Os Subtibiale in Young Athletes: A Cross-Sectional Study of 1,167 Athleteshttps://www.pharmaradar360.com/article/plexiform-neurofibromas-and-malignant-peripheral-nerve-sheath-tumors-in-adults-w-8eec82162b4e1d16Pharma Surgeen2026-07-07T00:00:00.000ZPlexiform Neurofibromas and Malignant Peripheral Nerve Sheath Tumors in Adults with Neurofibromatosis Type 1: Clinical Insights from a Large Cohorthttps://www.pharmaradar360.com/article/prediction-of-clinical-outcomes-based-on-phenotypic-grouping-using-left-ventricu-c375707dbcb727cdPharma Surgeen2026-07-07T00:00:00.000ZPrediction of Clinical Outcomes Based on Phenotypic Grouping Using Left Ventricular and Left Atrial Strains in Patients with HFpEFhttps://www.pharmaradar360.com/article/neurological-roots-of-emotional-ambivalence-from-brain-networks-to-clinical-impl-cb7d1d1de633acbcPharma Surgeen2026-07-07T00:00:00.000ZNeurological roots of emotional ambivalence: from brain networks to clinical implicationshttps://www.pharmaradar360.com/article/comment-on-effects-of-locally-applied-water-filtered-infrared-a-irradiation-adju-aea613ba30b63ea1Pharma Surgeen2026-07-07T00:00:00.000ZComment on ‘effects of locally applied water-filtered infrared a irradiation adjunctive to iloprost and carbon dioxide hand baths in patients with systemic sclerosis and severe Raynaud’s phenomenon – a randomized controlled trial’https://www.pharmaradar360.com/article/serum-reg3-as-a-biomarker-for-clinical-and-endoscopic-activity-in-ulcerative-col-3db607060c9ec88bPharma Surgeen2026-07-07T00:00:00.000ZSerum REG3α as a biomarker for clinical and endoscopic activity in ulcerative colitishttps://www.pharmaradar360.com/article/green-synthesis-of-tetrahydropyridine-3-carboxylate-derivatives-and-evaluation-o-ff3b58dacb597682Pharma Surgeen2026-07-07T00:00:00.000ZGreen synthesis of tetrahydropyridine-3-carboxylate derivatives and evaluation of antimicrobial and antimalarial activities supported by molecular docking, POM studies, and drug-likeness analysishttps://www.pharmaradar360.com/article/robust-higher-order-feedback-feedforward-ilc-for-networked-nonlinear-system-with-a55d5819d6b15e38Pharma Surgeen2026-07-07T00:00:00.000ZRobust higher-order feedback feedforward ILC for networked nonlinear system with varying trial lengths, data dropouts and disturbanceshttps://www.pharmaradar360.com/article/bispecific-10e8-4-imab-broadly-neutralizing-antibody-in-people-with-or-without-h-bd2f8ab82406ab0dPharma Surgeen2026-07-07T00:00:00.000ZBispecific 10E8.4/iMab broadly neutralizing antibody in people with or without HIV-1: a partially randomized phase 1 trialhttps://www.pharmaradar360.com/article/membrane-anchored-dna-nanodevice-with-allosteric-aptamer-arms-enables-parallel-p-80c38f126098b1d1Pharma Surgeen2026-07-07T00:00:00.000ZMembrane-anchored DNA nanodevice with allosteric aptamer arms enables parallel probing and on-site drug deliveryhttps://www.pharmaradar360.com/article/empowering-clinical-trial-design-with-agentic-intelligence-and-real-world-data-cc4c34f3683e4e50Pharma Surgeen2026-07-07T00:00:00.000ZEmpowering clinical trial design with agentic intelligence and real-world datahttps://www.pharmaradar360.com/article/measurable-residual-disease-is-not-a-universally-reliable-surrogate-for-progress-f64b95205d12bdfePharma Surgeen2026-07-07T00:00:00.000ZMeasurable residual disease is not a universally reliable surrogate for progression-free survival in clinical trials of new chronic lymphocytic leukemia therapieshttps://www.pharmaradar360.com/article/renal-involvement-in-leprosy-in-the-multidrug-therapy-era-current-evidence-and-c-975ceba670a70b2aPharma Surgeen2026-07-07T00:00:00.000ZRenal Involvement in Leprosy in the Multidrug Therapy Era: Current Evidence and Clinical Monitoringhttps://www.pharmaradar360.com/article/genetic-control-of-hypocotyl-and-ray-floret-color-in-newly-developed-genetic-sto-1ca7b99227c515c5Pharma Surgeen2026-07-07T00:00:00.000ZGenetic control of hypocotyl and ray floret color in newly developed genetic stock PYRS-1 of sunflower and mapping of ray floret color loci using simple sequence repeat markershttps://www.pharmaradar360.com/article/complement-component-c4b-prioritization-through-drug-target-mendelian-randomizat-87176a51cf4536dfPharma Surgeen2026-07-07T00:00:00.000ZComplement Component C4B Prioritization Through Drug‒Target Mendelian Randomization and Proteomic Analysis Reveals a Novel Therapeutic Target for Calcific Aortic Valve Stenosishttps://www.pharmaradar360.com/article/grafted-natural-polymers-emerging-tools-in-drug-delivery-and-biomedical-applicat-49d68927e9821c55Pharma Surgeen2026-07-07T00:00:00.000ZGrafted natural polymers: emerging tools in drug delivery and biomedical applicationshttps://www.pharmaradar360.com/article/multi-method-statistical-signal-aggregation-with-machine-learning-for-severity-c-13b8b5b1382f9dddPharma Surgeen2026-07-07T00:00:00.000ZMulti-method statistical signal aggregation with machine learning for severity classification of neonatal adverse drug reactionshttps://www.pharmaradar360.com/article/from-executor-to-orchestrator-the-pharmacology-scientist-in-the-age-of-agentic-s-8458c701b228ad16Pharma Surgeen2026-07-07T00:00:00.000ZFrom Executor to Orchestrator: The Pharmacology Scientist in the Age of Agentic <scp>AI</scp>https://www.pharmaradar360.com/article/nct07689019-effects-of-far-infrared-rays-and-transcutaneous-electrical-nerve-sti-918b7127dafd61d7Pharma Surgeen2026-07-07T00:00:00.000ZNCT07689019: Effects of Far Infrared Rays and Transcutaneous Electrical Nerve Stimulation on Short Term Prognosis of Head and Neck Cancer Patients Receiving Curative Treatmenthttps://www.pharmaradar360.com/article/nct07688980-study-to-characterise-pharmacokinetics-pk-pharmacodynamics-pd-and-sa-42183be3addec08fPharma Surgeen2026-07-07T00:00:00.000ZNCT07688980: Study to Characterise Pharmacokinetics (PK), Pharmacodynamics (PD), and Safety of Anifrolumab Administered Subcutaneously (SC) or Intravenously (IV)https://www.pharmaradar360.com/article/nct07688785-effects-of-basic-body-awareness-therapy-on-gait-and-plantar-pressure-a2c31d0613bd7680Pharma Surgeen2026-07-07T00:00:00.000ZNCT07688785: Effects of Basic Body Awareness Therapy on Gait and Plantar Pressure in Healthy Young Adultshttps://www.pharmaradar360.com/article/nct07687628-camera-based-endoscopy-allows-spontaneous-breathing-diagnostic-manag-818e07e2f86f401aPharma Surgeen2026-07-07T00:00:00.000ZNCT07687628: Camera-based Endoscopy Allows Spontaneous Breathing Diagnostic Management in Neonates With Tracheoesophageal Fistulahttps://www.pharmaradar360.com/article/nct07687342-pdca-based-precision-nursing-for-stroke-patients-with-tracheostomy-cc25d5703d09f456Pharma Surgeen2026-07-07T00:00:00.000ZNCT07687342: PDCA-Based Precision Nursing for Stroke Patients With Tracheostomyhttps://www.pharmaradar360.com/article/nct07687225-surgery-vs-no-surgery-for-primary-tumor-in-de-novo-stage-iv-breast-c-aa5dcb62a621ae9cPharma Surgeen2026-07-07T00:00:00.000ZNCT07687225: Surgery vs. No Surgery for Primary Tumor in De Novo Stage IV Breast Cancer With Solitary Bone Metastaseshttps://www.pharmaradar360.com/article/nct07687186-qishen-yiqi-dripping-pills-in-treatment-of-chronic-heart-failure-e3ea49c8e6b721e7Pharma Surgeen2026-07-07T00:00:00.000ZNCT07687186: Qishen Yiqi Dripping Pills in Treatment of Chronic Heart FailUrehttps://www.pharmaradar360.com/article/nct07683104-natural-history-of-trisomy-8-associated-autoinflammatory-disease-tri-a10b26c09d1352edPharma Surgeen2026-07-07T00:00:00.000ZNCT07683104: Natural History of Trisomy 8-Associated Autoinflammatory Disease (TRIAD) and Related Disordershttps://www.pharmaradar360.com/article/nct07651280-improving-the-reliability-of-llms-as-medical-assistants-for-the-gene-892a4e617796e9a9Pharma Surgeen2026-07-07T00:00:00.000ZNCT07651280: Improving the Reliability of LLMs as Medical Assistants for the General Publichttps://www.pharmaradar360.com/article/nct07638397-orthodontic-treatment-outcomes-of-self-ligating-system-compared-to-c-21f5cb8783854d76Pharma Surgeen2026-07-07T00:00:00.000ZNCT07638397: Orthodontic Treatment Outcomes of Self Ligating System Compared to Clear Aligner Systemhttps://www.pharmaradar360.com/article/nct07551570-pharmacokinetics-of-vc005-tablets-in-subjects-with-renal-impairment-ad9859636760a931Pharma Surgeen2026-07-07T00:00:00.000ZNCT07551570: Pharmacokinetics of VC005 Tablets in Subjects With Renal Impairment and Normal Renal Functionhttps://www.pharmaradar360.com/article/nct07517211-a-prospective-study-of-physical-function-in-adults-who-receive-syste-0773b821a1d010a0Pharma Surgeen2026-07-07T00:00:00.000ZNCT07517211: A Prospective Study of Physical Function in Adults Who Receive Systemic Therapy for Stage I-III Gastroesophageal Cancer, FAST-GO Studyhttps://www.pharmaradar360.com/article/nct07512089-comparison-of-presbyond-laser-blended-vision-and-conventional-monovi-dfc17769467fc6d7Pharma Surgeen2026-07-07T00:00:00.000ZNCT07512089: Comparison of PRESBYOND Laser Blended Vision and Conventional Monovision LASIK in Individuals With Presbyopia: A Randomized Clinical Studyhttps://www.pharmaradar360.com/article/nct07447973-multimodal-deep-learning-model-for-multi-task-diagnosis-and-triage-s-9dbe60234638e025Pharma Surgeen2026-07-07T00:00:00.000ZNCT07447973: Multimodal Deep Learning Model for Multi-task Diagnosis and Triage Suggestions of Ophthalmic Diseaseshttps://www.pharmaradar360.com/article/nct07413016-comparison-of-sensory-adapted-and-regular-dental-environments-in-pat-5089e800897f9f58Pharma Surgeen2026-07-07T00:00:00.000ZNCT07413016: Comparison of Sensory-Adapted and Regular Dental Environments in Patients With Mild Intellectual Disability and Moderate Dental Anxietyhttps://www.pharmaradar360.com/article/nct07406282-a-study-to-learn-about-real-world-utilization-and-outcomes-of-darolu-615cbf3901d63499Pharma Surgeen2026-07-07T00:00:00.000ZNCT07406282: A Study to Learn About Real-world Utilization and Outcomes of Darolutamide and Other Androgen Receptor Pathway Inhibitors (ARPIs) for Newly Diagnosed Metastatic Hormone-sensitive Prostate Cancer (de Novo mHSPC) in US Urology Clinicshttps://www.pharmaradar360.com/article/nct07396129-assessing-the-efficacy-of-a-high-dose-lidocaine-tetracaine-cream-for-48e3040c404c655cPharma Surgeen2026-07-07T00:00:00.000ZNCT07396129: Assessing the Efficacy of a High-Dose Lidocaine-Tetracaine Cream for the Treatment of Peripheral Neuropathic Painhttps://www.pharmaradar360.com/article/nct07345676-colorectal-cancer-screening-outreach-c3e7657abada564fPharma Surgeen2026-07-07T00:00:00.000ZNCT07345676: Colorectal Cancer Screening Outreachhttps://www.pharmaradar360.com/article/nct07344779-a-study-to-learn-how-men-with-advanced-prostate-cancer-respond-to-tr-f6daaa6f09d4690aPharma Surgeen2026-07-07T00:00:00.000ZNCT07344779: A Study to Learn How Men With Advanced Prostate Cancer Respond to Treatment With Darolutamide and Hormone Therapy, With or Without Chemotherapy, in Real-world Medical Practicehttps://www.pharmaradar360.com/article/nct07288177-study-to-assess-the-efficacy-and-safety-of-rina-s-in-participants-wi-ce738e274fe20667Pharma Surgeen2026-07-07T00:00:00.000ZNCT07288177: Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancerhttps://www.pharmaradar360.com/article/nct07255729-an-exosomal-microrna-signature-for-preoperative-staging-in-colon-can-4cde840658dd3236Pharma Surgeen2026-07-07T00:00:00.000ZNCT07255729: An Exosomal microRNA Signature for Preoperative Staging in Colon Cancerhttps://www.pharmaradar360.com/article/nct07224789-liquid-biopsy-for-early-detection-of-colorectal-cancer-using-circula-8bb42e3eb4eee43bPharma Surgeen2026-07-07T00:00:00.000ZNCT07224789: Liquid Biopsy for Early Detection of Colorectal Cancer Using Circular RNAhttps://www.pharmaradar360.com/article/nct07176975-a-study-to-test-how-well-different-doses-of-bi-1831169-in-combinatio-221d8bb7c81fe462Pharma Surgeen2026-07-07T00:00:00.000ZNCT07176975: A Study to Test How Well Different Doses of BI 1831169 in Combination With an Anti-PD1 Antibody Are Tolerated in Japanese People With Different Advanced Cancershttps://www.pharmaradar360.com/article/nct07005154-a-phase-2-study-to-evaluate-the-effects-of-asp5541-in-participants-w-9e9e208cfb506fbaPharma Surgeen2026-07-07T00:00:00.000ZNCT07005154: A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancerhttps://www.pharmaradar360.com/article/nct06964061-evaluate-efficacy-safety-tolerability-and-biodegradation-of-pa5346-o-3ba00c81dfe28de1Pharma Surgeen2026-07-07T00:00:00.000ZNCT06964061: Evaluate Efficacy, Safety, Tolerability and Biodegradation of PA5346 Ocular Implant in Patients With Open-Angle Glaucoma or Ocular Hypertensionhttps://www.pharmaradar360.com/article/nct06948097-syk-inhibition-in-mitigating-lung-allograft-rejection-similar-a-tria-28f73f1ac769add4Pharma Surgeen2026-07-07T00:00:00.000ZNCT06948097: Syk Inhibition in MItigating Lung Allograft Rejection (SIMILAR): A Trial to Evaluate the Safety and Tolerability of Fostamatinib in Lung Transplant Patients With Donor-Specific Antibodieshttps://www.pharmaradar360.com/article/nct06857851-optimizing-deep-brain-stimulation-to-improve-visuomotor-function-in-1dd8df3fedabb10cPharma Surgeen2026-07-07T00:00:00.000ZNCT06857851: Optimizing Deep Brain Stimulation to Improve Visuomotor Function in Parkinson's Diseasehttps://www.pharmaradar360.com/article/nct06755736-the-effect-of-superficial-cervical-block-application-on-postoperativ-a2248f13c1d8f7dcPharma Surgeen2026-07-07T00:00:00.000ZNCT06755736: The Effect of Superficial Cervical Block Application on Postoperative Opioid Consumption in Patients Undergoing Anterior Cervical Discectomy Surgeryhttps://www.pharmaradar360.com/article/nct06406465-a-ugt1a1-genotype-directed-study-of-belinostat-pharmacokinetics-and-bec826a8d1d0b74cPharma Surgeen2026-07-07T00:00:00.000ZNCT06406465: A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicityhttps://www.pharmaradar360.com/article/nct06327477-proton-spatially-fractionated-radiotherapy-and-standard-radiation-th-5099de6fe53839f7Pharma Surgeen2026-07-07T00:00:00.000ZNCT06327477: Proton-Spatially Fractionated Radiotherapy and Standard Radiation Therapy for the Treatment of Newly Diagnosed Retroperitoneal Soft Tissue Sarcomahttps://www.pharmaradar360.com/article/nct06052631-microneurographic-assessment-of-peripheral-nerves-in-healthy-volunte-19ef87b4db826563Pharma Surgeen2026-07-07T00:00:00.000ZNCT06052631: Microneurographic Assessment of Peripheral Nerves in Healthy Volunteers and Individuals With Sensory Dysfunction Caused by Inherited Mutations in the PIEZO2 Genehttps://www.pharmaradar360.com/article/nct05751486-a-clinical-study-to-evaluate-the-safety-and-tolerability-of-js001sc-8a508921d67bb5f1Pharma Surgeen2026-07-07T00:00:00.000ZNCT05751486: A Clinical Study to Evaluate the Safety and Tolerability of JS001sc in Advanced Nasopharyngeal Carcinomahttps://www.pharmaradar360.com/article/nct05136196-bicazo-a-study-combining-two-immunotherapies-cabozantinib-and-nivolu-3eb3d3ab47dbf20dPharma Surgeen2026-07-07T00:00:00.000ZNCT05136196: BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Studyhttps://www.pharmaradar360.com/article/nct05037968-magnetos-flex-matrix-compared-to-trinity-elite-mixed-with-local-auto-ea6186484cc0cc3aPharma Surgeen2026-07-07T00:00:00.000ZNCT05037968: MagnetOs Flex Matrix Compared to Trinity Elite Mixed With Local Autograft in Patients Undergoing up to Four-level Instrumented Posterolateral Fusionhttps://www.pharmaradar360.com/article/nct04824859-a-geriatric-assessment-electronic-platform-for-older-patients-with-c-8983c8ea281a7ac3Pharma Surgeen2026-07-07T00:00:00.000ZNCT04824859: A Geriatric Assessment Electronic Platform for Older Patients With Cancer (eGAP - Electronic Geriatric Assessment Platform)https://www.pharmaradar360.com/article/nct04765150-integrating-quantitative-mri-and-artificial-intelligence-to-improve-8c38fc87c032acfaPharma Surgeen2026-07-07T00:00:00.000ZNCT04765150: Integrating Quantitative MRI and Artificial Intelligence to Improve Prostate Cancer Classificationhttps://www.pharmaradar360.com/article/nct04542824-trial-of-the-safety-and-efficacy-of-epcoritamab-in-japanese-subjects-8f8b2e5edddf7421Pharma Surgeen2026-07-07T00:00:00.000ZNCT04542824: Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL)https://www.pharmaradar360.com/article/nct04437654-the-efficacy-and-safety-of-non-vitamin-k-antagonist-oral-anticoagula-9f017bd0e9f35ba6Pharma Surgeen2026-07-07T00:00:00.000ZNCT04437654: The Efficacy and Safety of Non-vItamiN K antaGonist oraL Anticoagulants for intermEdiate Stroke Risk in Patients With Atrial Fibrillation (SINGLE-AF)https://www.pharmaradar360.com/article/nct04315571-comparing-ascites-relief-in-two-standard-treatments-large-volume-par-d5c6064abbc227f5Pharma Surgeen2026-07-07T00:00:00.000ZNCT04315571: Comparing Ascites Relief In Two Standard Treatments: Large Volume Paracentesis Vs. Early Tips Using Viatorr Controlled Expansion Stentshttps://www.pharmaradar360.com/article/nct04083599-gen1042-safety-trial-and-anti-tumor-activity-in-participants-with-ma-2abc37867245ba71Pharma Surgeen2026-07-07T00:00:00.000ZNCT04083599: GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumorshttps://www.pharmaradar360.com/article/novartis-adc-gambit-regulation-as-catalyst-for-u-k-biotech-a-biocentury-podcast-49fc1aa668df0c86Pharma Surgeen2026-07-06T23:16:00.000ZNovartis’ ADC gambit & regulation as catalyst for U.K. biotech — a BioCentury podcasthttps://www.pharmaradar360.com/article/fda-names-former-pharmaceutical-company-executive-to-oversee-us-drug-program-544f80cbdd268c7ePharma Surgeen2026-07-06T23:11:03.000ZFDA names former pharmaceutical company executive to oversee US drug programhttps://www.pharmaradar360.com/article/why-biotech-cos-need-litigation-plans-before-bad-news-8674770d1a50eb5bPharma Surgeen2026-07-06T22:12:00.000ZWhy Biotech Cos. Need Litigation Plans Before Bad Newshttps://www.pharmaradar360.com/article/opus-genetics-stock-holds-buy-rating-at-btig-on-gene-therapy-progress-by-investi-1b1f57ff64f043f8Pharma Surgeen2026-07-06T21:16:34.000ZOpus Genetics stock holds Buy rating at BTIG on gene therapy progress By Investing.comhttps://www.pharmaradar360.com/article/a-former-fda-official-on-antidepressants-and-suicide-risk-108b951f3d91f52bPharma Surgeen2026-07-06T21:08:54.000ZA former FDA official on antidepressants and suicide riskhttps://www.pharmaradar360.com/article/vertex-acquires-crinetics-pharmaceuticals-for-10-billion-as-biotech-m-a-booms-56f4cda432dae9ecPharma Surgeen2026-07-06T20:55:46.000ZVertex acquires Crinetics Pharmaceuticals for $10 billion as biotech M&A boomshttps://www.pharmaradar360.com/article/to-be-labeled-a-success-econsent-must-deliver-on-promises-for-participants-sites-d9b08ffd97440a88Pharma Surgeen2026-07-06T20:23:43.000ZTo be Labeled a Success, eConsent Must Deliver on Promises for Participants, Sites, and Sponsorshttps://www.pharmaradar360.com/article/texas-biomed-teams-up-with-uk-based-biotech-company-to-fight-screwworm-c699c247130edca5Pharma Surgeen2026-07-06T19:25:00.000ZTexas Biomed teams up with UK-based biotech company to fight screwwormhttps://www.pharmaradar360.com/article/vera-therapeutics-jumps-9-as-fda-decision-on-kidney-drug-looms-27fce32923d30fb0Pharma Surgeen2026-07-06T19:06:00.000ZVera Therapeutics Jumps 9% as FDA Decision on Kidney Drug Loomshttps://www.pharmaradar360.com/article/veraxa-biotech-vrxa-highlights-bitac-pipeline-progress-advances-partnering-strat-5ab7787a8abc3c62Pharma Surgeen2026-07-06T19:00:00.000ZVERAXA Biotech (VRXA) Highlights BiTAC Pipeline Progress, Advances Partnering Strategyhttps://www.pharmaradar360.com/article/cmps-stock-rises-23-pre-market-as-compass-achieves-primary-endpoint-in-phase-3-t-4191aa06fc271c3ePharma Surgeen2026-07-06T18:54:54.000ZCMPS Stock Rises 23% Pre-Market As Compass Achieves Primary Endpoint In Phase 3 Treatment-Resistant Depression Trialhttps://www.pharmaradar360.com/article/mizuho-raises-revolution-stock-price-target-to-215-on-cancer-data-by-investing-c-573b023c9e2403a7Pharma Surgeen2026-07-06T18:23:43.000ZMizuho raises Revolution stock price target to $215 on cancer data By Investing.comhttps://www.pharmaradar360.com/article/b-riley-reiterates-buy-on-opus-genetics-stock-on-fda-alignment-by-investing-com-2caa3448242f6f2fPharma Surgeen2026-07-06T18:15:59.000ZB.Riley reiterates Buy on Opus Genetics stock on FDA alignment By Investing.comhttps://www.pharmaradar360.com/article/eli-lilly-and-vs-teva-which-pharmaceutical-stock-is-a-better-buy-in-2026-aa66898ab2b17046Pharma Surgeen2026-07-06T18:09:00.000ZEli Lilly and vs. Teva: Which Pharmaceutical Stock Is a Better Buy in 2026?https://www.pharmaradar360.com/article/novartis-buys-london-boston-biotech-for-up-to-1-5b-af92c8f25cce0ca2Pharma Surgeen2026-07-06T17:58:00.000ZNovartis buys London-Boston biotech for up to $1.5Bhttps://www.pharmaradar360.com/article/abbvie-announces-tepkinly-epcoritamab-in-combination-with-lenalidomide-and-ritux-3681d475b0e352acPharma Surgeen2026-07-06T17:45:00.000ZAbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphomahttps://www.pharmaradar360.com/article/new-partnership-aims-to-accelerate-development-of-cystic-fibrosis-therapy-04b5c8e9e0ccf64cPharma Surgeen2026-07-06T17:35:26.000ZNew partnership aims to accelerate development of cystic fibrosis therapyhttps://www.pharmaradar360.com/article/roche-pens-490m-astex-breast-cancer-license-deal-35a03c0939d092b6Pharma Surgeen2026-07-06T17:23:52.000ZRoche pens $490m Astex breast cancer license dealhttps://www.pharmaradar360.com/article/cordis-project-minimally-invasive-neuromodulation-implant-and-implantation-proce-6b9424108f032421Pharma Surgeen2026-07-06T17:23:31.000ZCORDIS project: Minimally Invasive Neuromodulation Implant and implantation procedure based on ground-breaking GRAPHene technology for treating brain disordershttps://www.pharmaradar360.com/article/the-new-rules-of-biotech-now-available-in-hardcover-and-audiobook-19cedd1e8096165aPharma Surgeen2026-07-06T17:23:10.000ZThe New Rules of Biotech Now Available in Hardcover and Audiobookhttps://www.pharmaradar360.com/article/cordis-project-integrated-services-for-infectious-disease-outbreak-research-53a1efcb4b0572e0Pharma Surgeen2026-07-06T17:21:40.000ZCORDIS project: Integrated Services for Infectious Disease Outbreak Researchhttps://www.pharmaradar360.com/article/cordis-project-smart-living-homes-whole-interventions-demonstrator-for-people-at-2c10cad06f08ec94Pharma Surgeen2026-07-06T17:06:07.000ZCORDIS project: SMART LIVING HOMES - WHOLE INTERVENTIONS DEMONSTRATOR FOR PEOPLE AT HEALTH AND SOCIAL RISKShttps://www.pharmaradar360.com/article/cordis-project-advancing-a-gmma-based-vaccine-against-invasive-non-typhoidal-sal-9be2f27526926dbcPharma Surgeen2026-07-06T17:06:04.000ZCORDIS project: Advancing a GMMA-based vaccine against invasive non-typhoidal salmonellosis through Phase 1 trial in Europe and sub-Saharan Africahttps://www.pharmaradar360.com/article/cordis-project-non-biased-fluorescent-dyes-as-markers-of-drugs-for-optical-in-ce-b2117c7245f75b0ePharma Surgeen2026-07-06T17:04:51.000ZCORDIS project: Non-biased fluorescent dyes as markers of drugs for optical in cellulo and in vivo imaginghttps://www.pharmaradar360.com/article/cordis-project-up-scaling-the-global-univocal-identification-of-medicines-72a91559ef9286baPharma Surgeen2026-07-06T17:04:45.000ZCORDIS project: Up-scaling the global univocal identification of medicineshttps://www.pharmaradar360.com/article/ataibeckley-completes-dosing-in-vls-01-depression-trial-by-investing-com-ede33bbfec44f8d1Pharma Surgeen2026-07-06T16:11:01.000ZAtaiBeckley completes dosing in VLS-01 depression trial By Investing.comhttps://www.pharmaradar360.com/article/inadvertent-vaccination-in-pregnancy-vip-778ef4ca08495cd2Pharma Surgeen2026-07-06T16:10:47.000ZInadvertent vaccination in pregnancy (VIP)https://www.pharmaradar360.com/article/new-survey-shows-collaboration-between-pharmaceutical-industry-and-uk-academia-i-9bd1328bcc9f738fPharma Surgeen2026-07-06T16:01:53.000ZNew survey shows collaboration between pharmaceutical industry and UK academia is growinghttps://www.pharmaradar360.com/article/hsbc-drops-pfizer-to-hold-seagen-adc-miss-leaves-43b-bet-without-catalyst-0e9f1cb5149a8d59Pharma Surgeen2026-07-06T15:58:22.000ZHSBC Drops Pfizer to Hold: Seagen ADC Miss Leaves $43B Bet Without Catalysthttps://www.pharmaradar360.com/article/biosimilar-race-heats-up-for-48-trillion-keytruda-market-a00759221a387a14Pharma Surgeen2026-07-06T15:38:21.000ZBiosimilar Race Heats Up for $48 Trillion Keytruda Markethttps://www.pharmaradar360.com/article/novartis-acquires-u-k-cancer-biotech-myricx-bio-for-1-5-billion-2eecdc96b2721668Pharma Surgeen2026-07-06T15:38:12.000ZNovartis acquires U.K. cancer biotech Myricx Bio for $1.5 billionhttps://www.pharmaradar360.com/article/northwell-names-entrepreneur-dr-brian-kim-biotech-chief-0fd68213490ae0b1Pharma Surgeen2026-07-06T15:35:28.000ZNorthwell names entrepreneur Dr. Brian Kim biotech chiefhttps://www.pharmaradar360.com/article/why-are-drugmakers-racing-to-acquire-adc-payload-platforms-4d516a05bf02467dPharma Surgeen2026-07-06T15:31:55.000ZWhy Are Drugmakers Racing to Acquire ADC Payload Platforms?https://www.pharmaradar360.com/article/can-vibration-therapy-prevent-bone-loss-f28b4de5e5d8a606Pharma Surgeen2026-07-06T15:16:52.000ZCan vibration therapy prevent bone loss?https://www.pharmaradar360.com/article/astrazeneca-plc-stock-azn-moved-down-by-3-79-on-jul-6-what-signal-does-it-send-02b2bb6c686f7b27Pharma Surgeen2026-07-06T15:15:10.000ZAstraZeneca PLC Stock (AZN) Moved Down by 3.79% on Jul 6: What Signal Does It Send?https://www.pharmaradar360.com/article/novartis-scoops-up-uk-biotech-myricx-in-1-5-billion-cancer-push-64d7440ff5c96e77Pharma Surgeen2026-07-06T15:13:20.000ZNovartis Scoops up UK Biotech Myricx in $1.5 Billion Cancer Pushhttps://www.pharmaradar360.com/article/milestone-alert-can-fite-completes-enrollment-in-phase-3-trial-of-oral-piclideno-1a6617f68a18c5c9Pharma Surgeen2026-07-06T15:08:34.000ZMilestone Alert: Can-Fite Completes Enrollment in Phase 3 Trial of Oral Piclidenoson for Psoriasishttps://www.pharmaradar360.com/article/fda-panel-to-evaluate-7-popular-peptides-for-compounding-substances-list-3f73690e7dd97803Pharma Surgeen2026-07-06T15:06:37.000ZFDA Panel to Evaluate 7 Popular Peptides for Compounding Substances Listhttps://www.pharmaradar360.com/article/incidental-cavitary-pulmonary-mycobacterium-avium-complex-disease-with-possible-db9bdc5aef660871Pharma Surgeen2026-07-06T15:06:04.000ZIncidental Cavitary Pulmonary Mycobacterium avium Complex Disease With Possible Haemophilus influenzae Coinfection and Pharmacologic Barriers to Therapy: A Case Reporthttps://www.pharmaradar360.com/article/clinical-trials-for-medicines-ending-a-clinical-trial-8d7a41f1e7e1b46ePharma Surgeen2026-07-06T15:02:31.000ZClinical trials for medicines: ending a clinical trialhttps://www.pharmaradar360.com/article/hair-loss-biotech-veradermics-up-656-since-its-ipo-credits-the-obesity-boom-7d6933cace8ee817Pharma Surgeen2026-07-06T14:56:30.000ZHair loss biotech Veradermics, up 656% since its IPO, credits the obesity boomhttps://www.pharmaradar360.com/article/clinical-investigations-for-medical-devices-5b914eac61a14f9cPharma Surgeen2026-07-06T14:54:37.000ZClinical investigations for medical deviceshttps://www.pharmaradar360.com/article/diphtheria-cases-among-asylum-seekers-in-england-2022-to-2026-3b388baae0a9b6b0Pharma Surgeen2026-07-06T14:50:54.000ZDiphtheria: cases among asylum seekers in England, 2022 to 2026https://www.pharmaradar360.com/article/new-haven-biotech-gets-one-year-notice-that-covid-therapy-s-emergency-authorizat-b1f482e9db6fb057Pharma Surgeen2026-07-06T14:38:14.000ZNew Haven biotech gets one-year notice that COVID therapy's emergency authorization will endhttps://www.pharmaradar360.com/article/the-ndaa-strengthens-government-support-for-biotech-it-can-be-even-stronger-59fff94b3e55ea54Pharma Surgeen2026-07-06T14:33:49.000ZThe NDAA Strengthens Government Support for Biotech. It Can Be Even Stronger.https://www.pharmaradar360.com/article/revolution-medicines-stock-hits-all-time-high-at-193-12-usd-ec310682154309b9Pharma Surgeen2026-07-06T14:29:28.000ZRevolution Medicines stock hits all-time high at 193.12 USDhttps://www.pharmaradar360.com/article/beyond-boston-unlikely-cities-stake-biotech-claims-c20c0c3b39ee70afPharma Surgeen2026-07-06T14:27:49.000ZBeyond Boston: Unlikely cities stake biotech claimshttps://www.pharmaradar360.com/article/the-evolution-and-impact-of-patient-support-services-a-strategic-framework-c6fe559337f961fePharma Surgeen2026-07-06T14:27:39.000ZThe Evolution and Impact of Patient Support Services: A Strategic Frameworkhttps://www.pharmaradar360.com/article/vertex-signs-letter-of-intent-loi-with-the-pan-canadian-pharmaceutical-alliance-7388369e90cd40daPharma Surgeen2026-07-06T14:22:00.000ZVertex Signs Letter of Intent (LOI) with the pan-Canadian Pharmaceutical Alliance for ALYFTREK for the Treatment of Cystic Fibrosis